Technical Analysis for EXAS - Exact Sciences Corporation

Grade Last Price % Change Price Change
B 64.17 -3.43% -2.28
EXAS closed down 3.43 percent on Wednesday, March 22, 2023, on 50 percent of normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Flat

Date Alert Name Type % Chg
Bearish Engulfing Bearish 0.00%
Fell Below 50 DMA Bearish 0.00%
MACD Bearish Signal Line Cross Bearish 0.00%
180 Bearish Setup Bearish Swing Setup 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
BB Squeeze Started Range Contraction 0.00%
Crossed Above 20 DMA Bullish -3.43%
Crossed Above 50 DMA Bullish -3.43%
MACD Bullish Signal Line Cross Bullish -3.43%
Gapped Up Strength -3.43%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Fell Below 50 DMA about 11 hours ago
Down 2 % about 11 hours ago
50 DMA Support about 11 hours ago
60 Minute Opening Range Breakdown about 12 hours ago
Rose Above Previous Day's High about 14 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Exact Sciences Corporation Description

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing diagnostic screening products for the early detection and prevention of colorectal pre-cancer and cancer. The company develops the Cologuard, a non-invasive stool-based DNA colorectal cancer screening test that is designed to detect pre-cancerous lesions or polyps, and each of the four stages of colorectal cancer. Its Cologuard test includes proprietary and patented methods that isolate and analyze the human DNA that are shed into stool every day from the exfoliation of cells that line the colon; and also protein marker to detect blood in the stool, utilizing an antibody-based fecal immunochemical test. The company's stool-based DNA colorectal cancer screening technology also focuses on the inflammatory bowel disease. It has collaboration, license, and purchase agreement with Genzyme Corporation, as well as with Mayo Clinic for developing tests to detect other gastro-intestinal cancers, primarily esophageal and pancreatic cancer. Exact Sciences Corporation was founded in 1995 and is headquartered in Madison, Wisconsin.


Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Medicine Cancer Medical Test Pancreatic Cancer Lab Testing Colorectal Cancer Inflammatory Bowel Disease Molecular Diagnostics Polyp Cancer Screening Genzyme Mayo Clinic Diagnostic Gastroenterology

Is EXAS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 76.94
52 Week Low 29.285
Average Volume 2,446,826
200-Day Moving Average 47.39
50-Day Moving Average 65.36
20-Day Moving Average 63.90
10-Day Moving Average 64.27
Average True Range 2.95
RSI 50.00
ADX 21.03
+DI 27.97
-DI 16.22
Chandelier Exit (Long, 3 ATRs) 60.62
Chandelier Exit (Short, 3 ATRs) 68.37
Upper Bollinger Bands 68.02
Lower Bollinger Band 59.78
Percent B (%b) 0.53
BandWidth 12.90
MACD Line 0.29
MACD Signal Line 0.30
MACD Histogram -0.0123
Fundamentals Value
Market Cap 9.65 Billion
Num Shares 150 Million
EPS -1.76
Price-to-Earnings (P/E) Ratio -36.40
Price-to-Sales 13.72
Price-to-Book 7.93
PEG Ratio -1.07
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 68.40
Resistance 3 (R3) 68.86 67.90 67.70
Resistance 2 (R2) 67.90 66.83 67.68 67.46
Resistance 1 (R1) 66.04 66.16 65.56 65.58 67.22
Pivot Point 65.08 65.08 64.85 64.86 65.08
Support 1 (S1) 63.22 64.01 62.74 62.76 61.12
Support 2 (S2) 62.26 63.34 62.04 60.88
Support 3 (S3) 60.40 62.26 60.65
Support 4 (S4) 59.94